The serine/threonine kinase human Pim1 (hereafter PIM1) cooperates with human c-Myc (hereafter MYC) in cell cycle progression and tumorigenesis. However, the nature of this cooperation is still unknown. Here we show that, after stimulation with growth factor, PIM1 forms a complex with the dimer of MYC with MAX (Myc-associated factor X) via the MYC BoxII (MBII) domain. MYC recruits PIM1 to the E boxes of the MYC-target genes FOSL1 (FRA-1) and ID2, and PIM1 phosphorylates serine 10 of histone H3 (H3S10) on the nucleosome at the MYC-binding sites, contributing to their transcriptional activation. MYC and PIM1 colocalize at sites of active transcription, and expression profile analysis revealed that PIM1 contributes to the regulation of 20% of the MYC-regulated genes. Moreover, PIM1-dependent H3S10 phosphorylation contributes to MYC transforming capacity. These results establish a new function for PIM1 as a MYC cofactor that phosphorylates the chromatin at MYC-target loci and suggest that nucleosome phosphorylation, at E boxes, contributes to MYC-dependent transcriptional activation and cellular transformation.
Chromatin structure has a crucial function in eukaryotic gene transcription. Several transcription activators have been shown to recruit chromatin-modifying activities, which mediate either covalent modifications of histones or ATP-dependent mobilization of nucleosomes. Covalent modifications of histones including acetylation, methylation, phosphorylation and ubiquitination have been associated with gene regulation 1, 2 . Phosphorylation of H3S10 has been connected with transcriptional activation in different organisms and with chromosome condensation during mitosis 3, 4 . In mammalian cells, stimulation with growth factors induces rapid phosphorylation of histone H3 at Ser 10 (H3S10) at c-Jun and c-Fos promoters mediated by mitogen-and stress-activated protein kinase (MSK)1, MSK2 and RSK2 kinases [4] [5] [6] [7] . In response to inflammatory cytokines, IκB kinase-α (IKK-α) phosphorylates H3S10 at NF-κB-responsive promoters 8, 9 . In this study we analysed the function of PIM1, a constitutively active serine/threonine kinase. Pim1 was first identified as a common insertion site in T-cell lymphomas induced by Moloney murine leukaemia virus (MMLV) 10 . RNA interference (RNAi) experiments demonstrated that PIM1 is essential for the cell cycle progression of human umbilical-vein endothelial cells (HUVECs) and for the differentiation of endothelial precursors in vitro 11 . Myc and Pim1 have been shown to cooperate in cell growth and transformation. Overexpression of Pim1 in transgenic mice demonstrated its cooperation with c-Myc in cell transformation [12] [13] [14] [15] , and microarray expression profiling showed that Pim1 is overexpressed in Myc-driven prostate tumours 16 . However, the nature of the cooperation of c-Myc and Pim1 in cell transformation is still unknown.
MYC codes for a basic helix-loop-helix leucine zipper transcription factor that binds to the E box (CACGTG) when dimerized with MAX and regulates the transcription of distinct genes involved in cell cycle progression, apoptosis, cell growth, and differentiation [17] [18] [19] [20] [21] [22] [23] . The DNAbinding domain of MYC is at the carboxy terminus. The MBII domain from the amino-terminal region that is essential for MYC-dependent cell transformation has been shown to recruit multiprotein enzymatic complexes to the MYC-activated genes 24 .
To understand the function of PIM1, we investigated the molecular connection between PIM1 and MYC. We propose that the recruitment of PIM1 to the chromatin by MYC contributes to the transcriptional activation of target genes for MYC by phosphorylating H3S10 at the E-box element and suggest that this cooperation is relevant for MYCdependent tumour formation.
RESulTS

PIM1 phosphorylates the nucleosome at H3S10
PIM1 messenger RNA is induced with fast kinetics in HUVECs treated with vascular endothelial growth factor (VEGF)-A 11 . On treatment with VEGF-A, PIM1 is induced and is localized in HUVEC nuclei within 40 min (see Supplementary Information, Fig. S1 ). As PIM1 is a serine/threonine kinase with putative consensus sites present on histones, its nuclear localization could account for the increase in H3 phosphorylation observed in these cells between 60 and 90 min after treatment with VEGF-A (see Supplementary Information, Fig. S1 ). We found that PIM1 could directly phosphorylate nucleosomes in vitro by incubating the recombinant glutathione S-transferase (GST)-PIM1 protein with chromatin fractions obtained from HEK 293 cells in the presence of [γ- 32 P]ATP. This analysis revealed that a single protein, with a molecular mass corresponding to H3, was phosphorylated by wild-type GST-PIM1 but not by the kinase-inactive mutant GST-PIM1-K67M (Fig. 1a, lanes 1-3) . Specific inhibition of nucleosome phosphorylation was observed in the presence of a peptide derived from the N terminus of H3 but not with a peptide derived from the N terminus of H2B or with an unrelated peptide (Fig. 1a, lanes 4-12) . PIM1 could phosphorylate reconstituted nucleosomes containing either recombinant wild-type H3 or H3S28A, but not nucleosomes assembled with the H3S10A mutant or the double mutant (Fig. 1b) , demonstrating that PIM1 phosphorylates H3 at Ser 10. Histone H3 co-immunoprecipitated with transiently expressed PIM1 or the kinase-inactive mutant, suggesting that PIM1 associates in vivo with the nucleosome (Fig. 1c) . Incubation of the immunoprecipitate in the presence of [γ- 32 P]ATP showed that the wild-type PIM1, but not the kinase-inactive mutant PIM1-K67M, phosphorylated H3. We conclude that PIM1 associates in vitro and in vivo with H3 and directly phosphorylates H3S10 on the nucleosome.
PIM1 forms a complex with MYC and MAX
Treatment with VEGF-A induces colocalization of MYC and PIM1 in the cell nucleus at 60 min, decreasing thereafter (Fig. 2a) . We tested whether PIM1 co-immunoprecipitates with MYC. A timecourse analysis in HUVECs treated with VEGF-A showed that, on Immunoprecipitations with anti-MAX antibodies at various time points showed the formation of the MAX-MYC complex from 60 min after stimulation with growth factor, thus corresponding to the appearance of MYC in the nucleus (Fig. 2b, right panel) . Importantly, PIM1 co-immunoprecipitated with MYC and MAX, suggesting that a complex containing PIM1 is formed. Endogenous PIM1 was also found to co-immunoprecipitate with endogenous MYC and MAX from HEK 293 cells after treatment with serum for 120 min (Fig. 2c) , thus demonstrating that a MAX-MYC-PIM1 endogenous complex is also formed in these cells.
As MYC-dependent cell transformation requires the MBII domain to bind cofactors either in a TRRAP (transformation/transcription domain-associated protein)-dependent or TRRAP-independent manner 24 , we tested whether PIM1 interacts with MYC at MBII through TRRAP. Wild-type Flag-MYC or MYC whose MBII domain had been deleted (Flag-MYC∆MBII) was expressed with PIM1 in HEK 293 cells and immunoprecipitated with either anti-Flag or anti-PIM1 antibodies. Western blot analysis showed reciprocal immunoprecipitation of Flag-MYC with PIM1, whereas co-immunoprecipitation was strongly reduced between Flag-MYC∆MBII and PIM1, suggesting that the MBII domain of MYC is required for the formation of a complex with PIM1 (Fig. 2d) . Endogenous TRRAP associated with MYC but not with Flag-MYC∆MBII, as described previously 25 . In contrast, PIM1 did not co-immunoprecipitate the endogenous TRRAP (Fig. 2d , lanes 5 and 10), suggesting that MYC forms independent complexes with PIM1 or TRRAP through the MBII domain.
PIM1 colocalizes with MYC on the chromatin at actively transcribing loci
To measure PIM1 and MYC association at MYC-target genes, we performed a nuclear distribution analysis of PIM1 with respect to MYC, nascent transcripts and chromatin markers. Quantitative analysis of double staining with anti-PIM1 and antibodies against different nuclear markers by sequential laser scanning (Fig. 3) showed a greater degree of PIM1 colocalization with MYC, with a Pearson's correlation coefficient (R r ) of 0.82 ± 0.06. PIM1 also showed an elevated overlap with phosphorylated H3S10 (H3S10ph) (R r 0.85 ± 0.07) and H3S10ph acetylated on Lys 14 (H3S10phK14ac), whereas little colocalization could be detected for PIM1 and dimethylation of H3K9 (R r 0.37 ± 0.03), a marker of silent heterochromatin. Furthermore, we analysed the nuclear distribution of PIM1 with respect to active transcription sites by in situ transcriptional run-on experiments. Double labelling revealed a high degree of overlap between PIM1 and sites of active transcription (R r 0.77 ± 0.05) with a pattern resembling that of transcription factories
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. A similar pattern of nuclear localization with respect to nascent transcripts was observed for MYC (R r 0.81 ± 0.09). Taken together, these results suggest that, after treatment with growth factor, PIM1 kinase is mostly localized with the transcription factor MYC at actively transcribing sites and with phosphorylated histones.
H3S10 phosphorylation at the FOSL1 enhancer is correlated with PIM1 association Next we analysed PIM1 association and H3S10 phosphorylation at FOSL1 (also known as FRA-1), a well-characterized MYC-target gene 27, 28 . FOSL1 contains an upstream functional serum response element (SRE), which is not sufficient to confer promoter activation but requires the activity of a downstream enhancer that is activated by MYC and AP-1 (refs 27-29). After treatment of HUVECs with VEGF-A, FOSL1 expression was induced with a peak at 60 min (Fig. 4a ). To demonstrate a direct binding of MYC and PIM1 to the FOSL1 regulatory sequences, chromatin immunoprecipitation (ChIP) followed by real-time quantitative polymerase chain reaction (PCR) analysis was performed at various time points after treatment with VEGF-A. As shown in Fig. 4b , we generated primers to analyse four FOSL1 regions: a FOSL1 upstream region containing a functional SRE and a non-canonical E-box element 30,31 (probe A), the downstream enhancer containing a canonical E box (probe B), a downstream region within the first intron (probe C), and a FOSL1 region within the second intron (probe D). Quantitative ChIP analysis with probe B revealed the transient recruitment to the FOSL1 enhancer of MYC and PIM1 at 60 min after treatment with VEGF-A simultaneously with a marked increase in H3S10ph signal (Fig. 4c) . ChIP with probe B also showed a significant increase in H3S10phK9ac and H3S10phK14ac, whereas H3K9acK14ac showed elevated levels before induction, suggesting that, at the FOSL1 enhancer, acetylation of H3 precedes binding of MYC and that phosphorylation of H3S10 takes place at the acetylated H3.
Analysis of the upstream element (probe A) revealed an association of MYC with this DNA fragment. PIM1 did not associate with this element, suggesting that the FOSL1 promoter is bound by an alternative MYC complex. This FOSL1 upstream element showed an increase in H3S10 phosphorylation at 15 min after treatment with VEGF-A, which was therefore not dependent on PIM1. As the FOSL1 SRE is constitutively occupied by the ternary complex factor (TCF), which is activated by the Ras/extracellular signal-regulated kinase (ERK) pathway 30 , we further analysed FOSL1 transcription and H3S10 phosphorylation in the presence of H89, a specific MSK1/MSK2 inhibitor 5 . Treatment of cells with H89 affected FOSL1 transcription, although a VEGF-A-dependent induction was still observed (Fig. 4d) . The analysis of H3S10ph signal showed specific inhibition of H3S10 phosphorylation at the FOSL1 upstream element but not at the enhancer (Fig. 4e) that phosphorylation at the upstream element and at the downstream enhancer are independent of each other and are mediated by different kinases. The acetylation pattern at the FOSL1 upstream element showed a significant increase in H3 phosphorylation and acetylation, with a peak between 15 and 30 min suggesting that, at this site, H3S10 phosphorylation precedes or is concomitant with H3 acetylation at Lys 9 and Lys 14, as described previously for immediate early (IE) promoters 3, 4 . The downstream FOSL1 fragments (analysed with probes C and D) did not reveal MYC or PIM1 binding or an increase in phosphorylated H3S10, but yielded elevated levels of acetylated H3. These results demonstrate specific recruitment of PIM1 to the FOSL1 enhancer simultaneously with an increase of H3S10 phosphorylation at this site and with transcriptional activation of the gene.
H3S10 phosphorylation at FOSL1 enhancer is mediated by PIM1
PIM1 depletion with small hairpin RNA (shRNA) was peformed to test whether PIM1 association with the FOSL1 enhancer was required for H3S10 phosporylation. In HEK 293 cells treated with serum MYC, PIM1 and FOSL1 showed a slower kinetics of induction than HUVECs treated with VEGF-A, possibly as a result of the different cell types (cell line versus primary cells). PIM1 silencing strongly inhibited FOSL1 mRNA expression (see below). Quantitative ChIP analysis ( Fig. 5b and see Supplementary Information, Fig. S2 ) showed a peak of H3S10 phosphorylation at the FOSL1 enhancer (probe B, as described in Fig. 4b ) at 120 min that was significantly decreased by PIM1 silencing, whereas ChIP analysis at the FOSL1 upstream element (probe A) showed a faster kinetics of H3S10 phosphorylation that was not affected by PIM1 knockdown. No H3S10 phosphorylation was observed at the downstream fragments (probes C and D). We concluded that H3S10 phosphorylation at the FOSL1 enhancer is dependent on PIM1.
PIM1 and MYC are found to associate at the FOSL1 enhancer with a peak between 90 and 120 min. PIM1 silencing significantly decreased PIM1 association at the enhancer without affecting MYC association. The overall pattern of H3 phosphoacetylation at Lys 9 and Lys 14 in HEK 293 cells showed higher levels of H3 acetylation already present before H3 phosphorylation at the FOSL1 enhancer (probe B) and along the FOSL1 gene (probes C and D), which was not affected by PIM1 silencing.
Moreover, expression of the kinase-inactive mutant PIM1-K67M significantly reduced H3S10ph levels at the FOSL1 enhancer (see Supplementary Information, Fig. S3 ) demonstrating that the kinase activity of PIM1 is required for H3S10 phosphorylation at this site. Mock PIM1 is recruited by MYC at the FOSL1 and ID2 E-box elements MYC silencing was performed to analyse whether its expression is required for the recruitment of PIM1 to the FOSL1 enhancer ( Fig. 6a and see Supplementary Information, Fig. S4 ). We also analysed the MYC-dependent recruitment of PIM1 at the ID2 E box. ID2 is a well-characterized MYC-regulated gene that, in contrast with FOSL1, contains its functional MYC-binding sites upstream from the promoter 28, 32 . As expected, ChIP analysis on control cells showed MYC association at the FOSL1 enhancer and the ID2 E box at 120 min after serum treatment, whereas MYC silencing significantly decreased MYC association at these sites ( Fig. 6b and see Supplementary Information, Fig. S4 ). ChIP analysis revealed PIM1 association with both genes in control cells, whereas MYC knockdown significantly decreased PIM1 association at these E boxes ( Fig. 6c and see Supplementary  Information, Fig. S4 ). Moreover, H3S10 phosphorylation showed a significant decrease in MYC-silenced cells at these sites ( Fig. 6d and see Supplementary Information, Fig. S4 ). In contrast, H3K9acK14ac was unaffected by MYC silencing ( These results establish that MYC, through its MBII domain, recruits PIM1 to the E-box elements of these MYC-regulated genes and that its recruitment is required for phosphorylating H3S10 at these sites.
PIM1 is required for transcriptional activation of FOSL1 and ID2 genes
After treatment of HEK 293 cells with serum, both FOSL1 and ID2 mRNA were induced with similar kinetics (Fig. 7b, e) , corresponding to the peak of PIM1 and MYC association and H3S10 phosphorylation in these cells. The same results were obtained by measuring FOSL1 and ID2 unprocessed heterogeneous nuclear RNA, indicating that increased mRNA levels depend on transcriptional activation. PIM1 silencing, as well as the expression of PIM1-K67M, inhibited the induction of both FOSL1 and ID2 transcripts (Fig. 7b , e and see Supplementary  Information, Fig. S3) , showing that PIM1 kinase activity is required for full transcriptional activation of both genes.
Quantitative ChIP analysis of RNA polymerase II (Pol II) and also Pol II phosphorylated on Ser 2 (Ser2P) at the C-terminal domain (CTD) of control cells revealed a significant increase in signal at FOSL1 and ID2 promoters and along the genes in response to treatment with serum (Fig. 7c, f and see Supplementary Information, Fig. S3 ) mirroring the increase in transcript levels. PIM1 silencing led to a specific decrease in Pol II signal at the promoters and within the coding regions. This decrease, however, could not account for the inhibition of the transcriptional activity mediated by the PIM1 silencing. By contrast, the decrease in the elongating Pol II (Pol II-Ser2P) along the gene was more closely correlated with transcript levels of both FOSL1 and ID2, suggesting that PIM1 silencing mostly affects the presence of Pol II engaged in transcript elongation.
PIM1 contributes to the regulation of a subgroup of MYCregulated genes
To understand the extent of PIM1 and MYC cooperation in gene transcription we performed an expression profile analysis of HEK 293 cells silenced either for MYC or PIM1 at 120 min after treatment with serum. MYC silencing affected the expression of 1026 genes, of which 818 were upregulated and 208 were downregulated (see Supplementary  Information, Table S1 ), in line with a previous analysis of MYC-regulated genes 33 . Comparison of genes regulated by MYC with those regulated by PIM1 showed that the latter contributes to the regulation of 207 of the 1026 MYC-regulated genes. Thus, 20% of MYC-regulated genes are also regulated by PIM1. Functional characterization of these genes, based on Gene Ontology categorization through the Panther database (http://www. pantherdb.org), revealed that nucleic acid metabolism, transcriptional regulation, RNA processing and oncogenesis are statistically overrepresented (P < 0.05) (see Supplementary Information, Tables S2 and S3 ). On the basis of this analysis we conclude that PIM1 acts as a cofactor for transcriptional regulation in a significant subset of MYC-dependent genes.
Recruitment of PIM1 to chromatin by MYC contributes to cell transformation
We next investigated the biological relevance of MYC-PIM1 cooperation. First we verified whether PIM1 contributes to the MYC-dependent regulation of cell cycle progression by silencing PIM1 in P493-6 cells, a cell line that depends on MYC expression for its proliferation 27, 34, 35 . Incorporation of [ 3 H]thymidine was significantly decreased in PIM1-silenced cells, and analysis of the cell cycle by fluorescence-activated cell sorting showed that PIM1 depletion determines a delay in progression of these cells through S phase (see Supplementary Information, Fig. S5 ).
To test whether cooperation of PIM1 with MYC in cell transformation and tumour growth is due to the role of PIM1 in the transcriptional activation of MYC-target genes, we performed transformation experiments in Rat-1 fibroblasts. Overexpression of MYC transforms these cells morphologically and induces them to grow in soft agar 36 . PIM1 silencing strongly inhibited the formation of soft-agar foci induced by MYC overexpression, and MYC silencing affected the number of foci induced by PIM1 overexpression to a similar extent (Fig. 8a) , showing that PIM1 is indeed required for MYC-dependent cell transformation. Moreover, overexpression of MYC and PIM1 generates a significantly greater number of colonies in soft agar than cells overexpressing either MYC or PIM1 (Fig. 8a, b) .
To understand whether PIM1 acts as a MYC cofactor in cell transformation, we generated chimaeric constructs in which PIM1 was directly fused to the N-terminal domain of MYC (PIM1-MYC). We found that the PIM1-MYC fusion molecule induced a comparable number of colonies in soft agar relative to the coexpression of MYC and PIM1 in the same cells (Fig. 8b) , suggesting that PIM1 recruitment to chromatin by MYC is required for cooperation between MYC and PIM1 in cell transformation. Because formation of the MYC complex with PIM1 and its recruitment to MYC-binding sites require the MBII domain (Figs 2 and 6), which is essential for the oncogenic activity of MYC, we also fused PIM1 to the transformation-defective MYC whose MBII domain had been deleted. We found that the fusion PIM1-MYC∆MBII, but not cotransfection of MYC∆MBII with PIM1, was able to rescue, at least in part, the defective MYC transformation (Fig. 8b) . This fusion rescues both transcriptional activity and the ability to phosphorylate H3S10 at its recruiting sites (Fig. 8d, f) . In contrast, a chimaeric molecule in which PIM1 was fused to a MYC∆C, a mutant unable to bind to the DNA, was defective for transforming activity and for phosphorylation of H3S10 at the target genes analysed (see Supplementary Information, Fig. S6 ). The transformed foci induced by the PIM1-MYC fusion grew vigorously in soft agar, forming bigger colonies than those induced by kinase-dead PIM1-MYC fusion (PIM1KD-MYC) (see Supplementary Information, Fig. S6 ).
Finally, we tested whether H3 phosphorylation at Ser 10 is required for MYC-dependent transformation by analysing MYC-transforming potential in the presence of yellow fluorescent protein (YFP) fused either to H3 (YFP-H3) or to H3 mutated at Ser 10 (YFP-H3S10A). Both fusion proteins localized together with the endogenous H3S10ph in the nucleus during interphase and mitosis (see Supplementary  Information, Fig. S7 ) and they did not interfere with cell cycle progression (see Supplementary Information, Fig. S7 ), in agreement with previous experiments with other histone fusion proteins 37 . We then performed transformation assays by expressing MYC, PIM1 or PIM1-MYC fusion proteins in these cells (see Supplementary Information,  Fig. S8 ). We observed that whereas YFP-H3 did not affect the number of foci, the YFP-H3S10A mutant significantly decreased the number of colonies in soft agar, the transcription of FOSL1 and ID2 and the phosphorylation of H3 at their MYC-binding sites (see Supplementary  Information, Fig. S8 ).
Taken together, these results show that H3 phosphorylation at MYCtarget genes by PIM1 is required for the cooperative effects of PIM1 and MYC in cell transformation.
DISCuSSIon
This study defines a new role for the serine/threonine kinase PIM1 as a MYC-dependent modifier of chromatin. On the basis of biochemical and functional evidence, we show that after stimulation with growth factor, a MYC-MAX-PIM1 complex formed in the nucleus, recruits PIM1 to the chromatin, where it phosphorylates histone H3 at Ser 10. This PIM1-dependent nucleosome phosphorylation is required for the transcriptional activation of a subset of MYC-target genes and MYCdependent cell transformation. 
ChIP analysis ChIP analysis Immunoprecipitation experiments showed that after stimulation with growth factor, MYC, in conjunction with MAX, forms a complex with PIM1 in the nucleus. Silencing experiments demonstrated that MYC is required for the recruitment of PIM1 to the chromatin, whereas PIM1 is necessary to phosphorylate H3 at Ser 10 on the nucleosome at E boxes to activate transcription. According to the current view, phosphorylation at the N-terminal domain of H3 could be required either to loosen the interaction between DNA and nucleosome and/or to generate a platform to recruit additional regulatory factors as described in the 'histone code' hypothesis 1 . PIM1-dependent phosphorylation at the FOSL1 and ID2 genes is specific for its recruitment sites and does not spread over the genes, suggesting that this phosphorylation is necessary to activate the enhancer.
It was shown previously that, after treatment with growth factors, H3 is phosphorylated at Ser 10 with fast kinetics by MSK1/MSK2 (refs 4-7). FOSL1 shows two regions with different phosphorylation kinetics of H3S10: a phosphorylation site at the upstream SRE, occurring within 15-30 min as a result of MSK1/MSK2 action, and phosphorylation at the enhancer that was coincident with the peak of transcriptional activation of the gene mediated by PIM1. These two regions behaved differently with regard to the acetylation of H3 at Lys 9 and Lys 14. Whereas at the FOSL1 promoter H3 phosphorylation and acetylation are tightly coupled, as shown previously for other IE promoters 3, [38] [39] [40] , at the FOSL1 enhancer the phosphorylation of H3S10 takes place in a region highly acetylated at H3 before the binding of MYC and PIM1. This is in agreement with the finding that for recognition by MYC, its target sites must be highly acetylated in H3 as well as methylated in H3K4/K79 (ref. 41 ). On the FOSL1 enhancer, the phosphorylation and acetylation of H3 might have distinct functional roles because PIM1-dependent phosphorylation of H3S10 is transient and limited to the E-box element whereas acetylation at Lys 9 and Lys 14 is more stable and distributed along the gene, suggesting that phosphorylation at these elements is a critical step in transcriptional activation. The fast turnover of H3 phosphorylation observed in our experiments, and its temporal coincidence with transcriptional activation, might be a general phenomenon because H3 phosphorylation was previously detected during transcriptional activation of heat shock genes in Drosophila and during induction of the RAR-β2 gene by retinoic agonists in murine P19 embryonal cells whereas acetylation was constitutive at these loci 42, 43 . It has been estimated that about 11% of cellular genes present a functional E box with which MYC can associate on the genome 28 . MYC silencing demonstrated that MYC recruits PIM1 at specific MYC-binding sites, and confocal microscopy showed an elevated degree of nuclear colocalization of PIM1 with nascent transcripts and with MYC after treatment with growth factor, suggesting that at this stage of the cell cycle PIM1 is recruited by MYC to a large number of sites. A gene expression profile analysis of genes regulated by MYC and PIM1 in cells treated with serum at 120 min revealed that 207 transcripts corresponding to 20% of MYC-regulated genes also require PIM1 for their regulation. The co-regulation includes genes involved in cell metabolism, protein synthesis, cycle progression and oncogenesis. A large number of these genes are transcriptional factors, which suggests that PIM1 participates in MYC-dependent regulatory networks. In agreement with these data, cell cycle analysis in PIM1 knockdown cells revealed decreased entry into S phase. Transformation analysis showed a more marked PIM1 effect because PIM1 silencing strongly inhibited the formation of MYC-dependent transformed colonies in soft agar. Although our experiments do not exclude the possibility that specific PIM1-regulated genes cooperate with MYC in cell transformation, our data strongly suggest that PIM1-dependent phosphorylation of H3 at MYC-target genes is necessary to regulate key genes required for MYC-dependent oncogenic transformation. In fact, fusion of PIM1 to the transformation-defective MYC∆MBII could rescue its transforming potential as well as H3 phosphorylation at MYC-binding sites, whereas PIM1 coexpression with MYC∆MBII did not lead to rescue.
This study therefore provides a molecular mechanism for MYC and PIM1 cooperation in gene regulation and oncogenic transformation. Because mutations that alter MYC expression are among the most common found in human and animal cancers 44 , it is conceivable that inhibiting MYC association with PIM1 and/or inhibiting PIM1 kinase activity by specific drugs might represent a method for the treatment of cancers in humans.
METHoDS
DNA constructs.
Human PIM1 and MYC complementary DNA were cloned into pcDNA5/FRT (Invitrogen, Carlsbad, CA, USA) vector under the control of the CMV/TetO2 tetracycline-inducible promoter. The PIM1-K67M construct was generated by introducing a site-specific mutation in the DNA sequence corresponding to Lys 67 to mutate it into a methionine residue (K67M). The MYC∆MBII construct was obtained by deleting the DNA sequence corresponding to amino-acid residues 119-152. The MYC∆C construct was obtained by deleting the DNA sequence corresponding to amino-acid residues 353-439. The PIM1-MYC fusion constructs were obtained by fusing the cDNA corresponding to PIM1 or PIM1-K67M by means of a ten-glycine encoding linker sequence to the cDNA corresponding to MYC, MYC∆MBII or MYC∆C.
shRNA constructs were obtained by cloning a double-stranded DNA cassette into the pENTR/H1/TO vector, which allows the expression of shRNA under the control of the tetracycline-inducible H1 promoter TetO2.
To generate shRNA cassettes the following oligonucleotides were designed in accordance with the manufacturer's protocol. The 21-nucleotide positive strands were the following: PIM1 shRNA#1 (shPIM1#1), 5ʹ-GTCTCTTCAGAGTGTCAGCAC-3ʹ; PIM1 shRNA scrambled control#1 (shsP#1), 5ʹ-GACTCATCAGTATGTTAGCAT-3ʹ; PIM1 shRNA#2 (shPIM1#2), 5ʹ-GAGGAAGAGAGTATCTATGGG-3ʹ; PIM1 shRNA scramble control#2 (shsP#2), 5ʹ-GAAGCCGAGAGTATCTATGTT-3ʹ; PIM1 shRNA#3 (shPIM1#3), 5ʹ-CGAAGAAATCCAGGACCATCC-3ʹ; PIM1 shRNA scrambled control#3 (shsP#3), 5ʹ-AAGTCATCCGAAGACCACAAC-3ʹ; PIM1 shRNA#4 (shPIM1#4), 5ʹ-ACGTGGAGAAGGACCGGATTT-3ʹ; PIM1 shRNA scrambled control #4 (shsP#4), 5ʹ-GATTCGAGGACATGGACTGAG-3ʹ; c-MYC shRNA#1 (shMYC#1), 5ʹ-GCAATCACCTATGAACTTGTT-3ʹ; c-MYC shRNA scramble control#1 (shsM#1), 5ʹ-GCATTCACCTAAGAAGTTCTT-3ʹ; c-MYC shRNA#2 (shMYC#2), 5ʹ-GACGACGAGACCTTCATCAAA-3ʹ; c-MYC shRNA2 scramble control #2 (shMYC#2), 5ʹ-AGATCCAACCAGTCAGGACAT-3ʹ; c-MYC shRNA#3 (shMYC#3), 5ʹ-CCTGAGACAGATCAGCAACAA-3ʹ; c-MYC shRNA scramble control#3 (shsM#3), 5ʹ-CAACATGGTAACGAACAGCAA-3ʹ; c-MYC shRNA#4 (shMYC#4), 5ʹ-CAGTTGAAACACAAACTTGAA-3ʹ; c-MYC shRNA scramble control#4 (shsM#4), 5ʹ-AACTAAGGTAACTATGCACAA-3ʹ; c-MYC shRNA#5 (shMYC#5), 5ʹ-CCATAATGTAAACTGCCTCAA-3ʹ; c-MYC shRNA scramble control #5 (shsM#5), 5ʹ-GCAATGACCACCTATTCAATA-3ʹ.
The recombinant GST-PIM1 construct was obtained by cloning the wild-type PIM1 and PIM1-K67M cDNA into the bacterial expression vector pGEX-4T; the fused protein was expressed and purified with a standard protocol.
The vectors coding for Xenopus laevis histones were expressed and purified as described previously 45 . Mutant recombinant histones H3 (H3S10A, H3S28A and H3S10A/S28A) were obtained by site-directed mutagenesis as described previously 46 . YFP-H3 was kindly provided by M. Bianchi (Milan, Italy) and mutagenized as described previously 46 .
Cell culture condition. We generated a tetracycline-inducible HEK 293 cell line stably expressing wild-type PIM1 or PIM1-K67M with the use of the Flp-T-Rex System from Invitrogen. Selected clones were cultivated for two or three weeks in DMEM containing 10% fetal bovine serum (FBS; Sigma) and 150 µg ml −1 hygromycin. For time-course experiments, HEK 293 cells were synchronized and then treated with 50% serum shock as described 47 . Primary HUVECs were grown in M199 medium supplemented with 15% FBS, brain protein extracts and heparin (50 µg ml −1 ). The cells were then starved for 24 h in M199 medium containing 1% FBS and 0.5% BSA and induced with 50 ng ml −1 VEGF-A. The cell line P493-6 (kindly provided by B. Amati, Milan, Italy) was grown in RPMI 1640 containing 10% FCS, 100 U ml −1 penicillin, 100 µg ml −1 streptomycin and 2 mM l-glutamine. MYC repression was obtained with 0.1 µg ml −1 tetracycline. MYC induction was obtained by washing the cells three times with tetracycline-free PBS containing 10% FCS, as described previously 27 .
Immunostaining and colocalization analysis. Colocalization experiments were performed on fixed cells as described previously 11 , with a TCS SP2 confocal microscope (Leica, Wetzlar, Germany). To label nascent RNA, anti-BrUTP (Sigma catalogue no. B2531) was used in permeabilized cells and immunodetected with small modifications from a previously described protocol 48 . The degree of double staining was measured by quantitative analysis of overlapping pixels by using Image J version 1.32j software (NIH, Bethesda, MD, USA). All pixels with the same position in both images were considered coincident and the brightness level of each pixel was plotted on the x and y axes of a scatter diagram. Two completely overlapping images would result in a straight diagonal line in the scatter diagram.
Protein immunoprecipitation, interaction assays, kinase assays and chromatin immunoprecipitation. Proteins were extracted by using F-buffer (10 mM Tris buffer pH 7.0, 50 mM NaCl, 30 mM Na 2 HPO 4 , 50 mM NaF, 5 µM ZnCl 2 , 1% Triton-X 100) and treated with 1 U ml −1 micrococcal nuclease (Sigma) at 40 °C for 1 h to obtain the chromatin proteins (chromatin fraction).
To identify interacting protein, 0.5 mg of total protein was incubated overnight at 4 °C with 3 µg of specific antibody. Immunocomplexes were incubated with Protein-A-conjugated or Protein-G-conjugated magnetic beads (Dynal, Oslo, Norway) for 30 min at 4 °C. Samples were washed four times with F buffer and twice with F-buffer containing 0.15 M NaCl, for 20 min at 4 °C. Proteins were eluted by boiling the samples and analysed by western blotting.
The GST interaction assay was performed by incubating 1 mg of protein extracts (derived from chromatin fractions) with recombinant proteins GST, GST-PIM1 wild-type (WT) and GST-PIM1-K67M bound to Glutathione-Sepharose resin (Amersham, Piscataway, NJ, USA). To allow specific interactions, proteins were incubated in interaction buffer (20 mM Tris buffer pH 8.0, 200 mM KCl, 10 mM dithiothreitol, 0.1 mM EGTA, 20% glycerol and inhibitor protease cocktail) for 2 h at 4 °C in the presence of 21-residue peptides. Unbound proteins were eliminated by three washes in the same buffer followed by protein equilibration in kinase buffer (30 mM Tris buffer, 10 mM dithiothreitol; 0.1 mM EGTA, 2 mM MnCl 2 , 10% glycerol). Kinase assay was performed by incubating samples in the same buffer in the presence of 4 pmol of [γ-32 P]ATP for 2 min at 30 °C. The reaction was stopped by the addition of 10 mM EDTA and samples were washed six times with kinase buffer containing 10 mM EDTA and 200 mM KCl. Phosphorylated proteins were separated by SDS-PAGE and revealed by autoradiography.
The reconstitution of nucleosome core particles was performed as described 49 . ChIP assays were performed as described by Upstate Protocols (http://www. upstate.com). DNA was analysed by quantitative real-time PCR with the use of Light Cycler DNA Amplification Kit SYBR Green I (Roche, Mannheim, Germany). All experiment values were normalized to those obtained with a nonimmune serum and divided by the input, using the procedure described previously 50 . Experiments on inhibition by MSK1/MSK2 were performed by incubating cells with H89 (Calbiochem, San Diego, CA, USA) as described previously 5 . Quantitative RT-PCR analysis was performed as described previously 11 .
Cell transformation and colony formation in soft agarose. The analysis of cell transformation and anchorage-independent growth were performed as described previously 36 . Cells transfected with the constructs indicated were suspended at about 10 4 cells in 2 ml of 0.35% low-melting agarose in a 35-mm culture dish containing 0.7% agarose base. Triplicates were prepared for each tested construct and inspected by eye after staining with crystal violet for colony formation after incubation at 37 °C for 10-14 days. Efficiency of transfection was measured with a reporter gene encoding green fluorescent protein, and the levels of proteins were compared by western blotting. Data analysis was performed by using GeneSpring software (Agilent Technologies). Filtering was performed across all arrays to remove spots that were at or below the background levels. Arrays were then examined individually and filtered to create lists of genes for those features that had a fold change of greater than or equal to 2 between the two channels. These lists were combined in Venn diagrams to create lists of genes that were common between pairs of samples. A list of genes demonstrating all of the changing features across the 4 arrays was used to create a cluster using a Pearson Correlation and average linkage. Gene clustering analysis was performed with PANTHER gene expression data analysis (www.pantherdb.org). The microarray data are deposited in Gene expression omnibus (GEO www.ncbi.nlm.nih.gov/geo) with accession number GSE7960. 
